NST for patients with MDS receiving matched sibling or matched unrelated donor (MUD) grafts.
| Total No. . | Donors . | Conditioning . | Status (No.) . | Engraftment . | Alive & Disease-free . | Center . |
|---|---|---|---|---|---|---|
| 8 | Sibling | Fludarabine/Bu/ATG | RAEB (3) | 3/3 | 3/3 | Jerusalem, Israel |
| Second RAEB (5) | 5/5 | 2/5 | ||||
| 4 | Sibling | Flag/Ida or 2CDA/araC | First CR (2) | 3/4 | 2/4 | Houston, Texas, USA |
| Relapse (2) | ||||||
| 4 | Sibling | Fludarabine/melphalan* | Relapse (4) | 4/4 | 1/4 | Houston, Texas, USA |
| 4 | MUD | Fludarabine/melphalan* | Relapse (4) | 4/4 | 1/4 | Houston, Texas, USA |
| 5 | MUD | Fludarabine/Bu/ATG | RAEB-T (3) | 3/5 | 1/5 | Dresden, Germany |
| RAEB (1) | ||||||
| Third PR (1) | ||||||
| Abbreviations: Bu, busulfan; ATG, antithymocyte globulin; Flag/Ida, fludarabine, cytosine arabinoside, G-CSF, and idarubicin; RAEB-T, refractory anemia with excess blasts in transformation | ||||||
| Total No. . | Donors . | Conditioning . | Status (No.) . | Engraftment . | Alive & Disease-free . | Center . |
|---|---|---|---|---|---|---|
| 8 | Sibling | Fludarabine/Bu/ATG | RAEB (3) | 3/3 | 3/3 | Jerusalem, Israel |
| Second RAEB (5) | 5/5 | 2/5 | ||||
| 4 | Sibling | Flag/Ida or 2CDA/araC | First CR (2) | 3/4 | 2/4 | Houston, Texas, USA |
| Relapse (2) | ||||||
| 4 | Sibling | Fludarabine/melphalan* | Relapse (4) | 4/4 | 1/4 | Houston, Texas, USA |
| 4 | MUD | Fludarabine/melphalan* | Relapse (4) | 4/4 | 1/4 | Houston, Texas, USA |
| 5 | MUD | Fludarabine/Bu/ATG | RAEB-T (3) | 3/5 | 1/5 | Dresden, Germany |
| RAEB (1) | ||||||
| Third PR (1) | ||||||
| Abbreviations: Bu, busulfan; ATG, antithymocyte globulin; Flag/Ida, fludarabine, cytosine arabinoside, G-CSF, and idarubicin; RAEB-T, refractory anemia with excess blasts in transformation | ||||||
140 or 180 mg/m2